

**Claim 1** (Presently Canceled)

**Claim 2** (Presently Canceled)

**Claim 3** (Presently Canceled)

**Claim 4** (Presently Canceled)

**Claim 5** (Presently Canceled)

**Claim 6** (Presently Canceled)

**Claim 7** (Presently Amended)      ~~The~~ A compound of **Claim 1** selected from the group consisting of:

{[5-(2,4-Diaminopyrimidin-6-yl)pentanoyl]-(N-methyl)amino}-3-(6-methoxypyridin-3-yl)-propanoic acid;

{[5-(2,4-Diaminopyrimidin-6-yl)pentanoyl]-(N-methyl)amino-3(R)-(6- methoxypyridin-3-yl)-propanoic acid;

{[5-(2,4-Diaminopyrimidin-6-yl)pentanoyl]-(N-methyl)amino-3(S)-(6- methoxypyridin-3-yl)-propanoic acid;

{[5-(3-Amino-5,6,7,8-tetrahydroisoquinolin-1-yl)pentanoyl]-(N-methyl)amino}-3-(6-methoxypyridin-3-yl)-propanoic acid;

{[5-(3-Amino-5,6,7,8-tetrahydroisoquinolin-1-yl)pentanoyl]-(N-methyl)amino}-3(R)-(6-methoxypyridin-3-yl)-propanoic acid;

{[5-(3-Amino-5,6,7,8-tetrahydroisoquinolin-1-yl)pentanoyl]-(N-methyl)amino}-3(S)-(6-methoxypyridin-3-yl)-propanoic acid;

9-(2,4-Diaminopyrimidin-6-yl)-3-(quinolin-3-yl)-nonanoic acid;

9-(2,4-Diaminopyrimidin-6-yl)-3(R)-(quinolin-3-yl)-nonanoic acid;

9-(2,4-Diaminopyrimidin-6-yl)-3(S)-(quinolin-3-yl)-nonanoic acid;

3(2-Methyl-pyrimidin-5-yl)-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid;

3(R)-(2-Methyl-pyrimidin-5-yl)-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid;

3(S)-(2-Methyl-pyrimidin-5-yl)-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid;

3-Pyrimidin-5-yl-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid;

3(R)-Pyrimidin-5-yl-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid;

3(S)-Pyrimidin-5-yl-9-(6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-2-yl)-nonanoic acid;

(2-Methyl-pyrimidin-5-yl)-9-(1,4,5,6-tetrahydro-pyrimidin-2-ylcarbamoyl)-nonanoic acid;

3(R)-(2-Methyl-pyrimidin-5-yl)-9-(1,4,5,6-tetrahydro-pyrimidin-2-ylcarbamoyl)-nonanoic acid;

3(S)-(2-Methyl-pyrimidin-5-yl)-9-(1,4,5,6-tetrahydro-pyrimidin-2-ylcarbamoyl)-nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3-(dihydrobenzofuran-6-yl)-nonanoic acid;

9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(R)-(dihydrobenzofuran-6-yl)-nonanoic acid;

9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(S)-(dihydrobenzofuran-6-yl)-nonanoic acid;

9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3-(6-methoxypyridin-3-yl)nonanoic acid;

9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(R)-(6-methoxypyridin-3-yl)nonanoic acid;

9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(S)-(6-methoxypyridin-3-yl)nonanoic acid;

9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3-(2-methoxypyrimidin-5-yl)nonanoic acid;

9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(R)-(2-methoxypyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(S)-(2-methoxypyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(R)-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(S)-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(R)-(2-methylpyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(S)-(2-methylpyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3-(quinoxalin-2-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(R)-(quinoxalin-2-yl)nonanoic acid;  
9-(4-Amino-2-ethylaminopyrimidin-6-yl)-3(S)-(quinoxalin-2-yl)nonanoic acid;  
9-(2-Amino-4-ethylaminopyrimidin-6-yl)-3-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(2-Amino-4-ethylaminopyrimidin-6-yl)-3(R)-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(2-Amino-4-ethylaminopyrimidin-6-yl)-3(S)-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-aminopyrimidin-6-yl)-3-(2-methylpyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-aminopyrimidin-6-yl)-3(R)-(2-methylpyrimidin-5-yl)nonanoic acid;  
9-(4-Amino-2-aminopyrimidin-6-yl)-3(S)-(2-methylpyrimidin-5-yl)nonanoic acid;  
9-(2-Ethylaminopyrimidin-6-yl)-3-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(2-Ethylaminopyrimidin-6-yl)-3(R)-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
9-(2-Ethylaminopyrimidin-6-yl)-3(S)-(2-ethoxypyrimidin-5-yl)nonanoic acid;  
and

3-(2-Methyl-pyrimidin-5-yl)-10-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-decanoic acid;

or a pharmaceutically acceptable salt thereof.

**Claim 8 (Previously Canceled)**

**Claim 9 (Presently Amended)** A pharmaceutical composition comprising a compound according to Claim 4 7 and a pharmaceutically acceptable carrier.

**Claim 10 (Presently Withdrawn)** The composition of Claim 9 which further comprises an active ingredient selected from the group consisting of

- a) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof,
- b) an estrogen receptor modulator,
- c) an androgen receptor modulator,
- d) a cytotoxic/antiproliferative agent,
- e) a matrix metalloproteinase inhibitor,
- f) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factors,
- g) an inhibitor of VEGF,
- h) an antibody to a growth factor or a growth factor receptor,
- i) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tie-1,
- j) a cathepsin K inhibitor,
- k) a growth hormone secretagogue,
- l) an inhibitor of osteoclast proton ATPase,
- m) an inhibitor of urokinase plasminogen activator (u-PA),
- n) a tumor-specific antibody-interleukin-2 fusion protein,
- o) an inhibitor of HMG-CoA reductase, and
- p) a farnesyl transferase inhibitor or a geranylgeranyl transferase inhibitor or a dual farnesyl/geranylgeranyl transferase inhibitor;  
and mixtures thereof.

**Claim 11 (Presently Withdrawn)** The composition of Claim 10 wherein said active ingredient is selected from the group consisting of

- a) an organic bisphosphonate or a pharmaceutically acceptable salt or ester thereof,
- b) an estrogen receptor modulator,
- c) an androgen receptor modulator,

- d) a cathepsin K inhibitor,
- e) an HMG-CoA reductase inhibitor, and
- f) an inhibitor of osteoclast proton ATPase;  
and mixtures thereof.

**Claim 12 (Presently Withdrawn)** The composition of Claim 11 wherein said organic bisphosphonate or pharmaceutically acceptable salt or ester thereof is alendronate monosodium trihydrate.

**Claim 13 (Presently Withdrawn)** A method of eliciting an  $\alpha v$  integrin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound according to Claim 1.

**Claim 14 (Presently Withdrawn)** The method of Claim 13 wherein  $\alpha v$  the integrin receptor antagonizing effect is an  $\alpha v\beta 3$  antagonizing effect.

**Claim 15 (Presently Withdrawn)** The method of Claim 14 wherein the  $\alpha v\beta 3$  antagonizing effect is selected from the group consisting of inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth.

**Claim 16 (Presently Withdrawn)** The method of Claim 15 wherein the  $\alpha v\beta 3$  antagonizing effect is the inhibition of bone resorption.

**Claim 17 (Presently Withdrawn)** A method of treating or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound according to Claim 1.

**Claim 18 (Presently Withdrawn)** The method of Claim 12 wherein the  $\alpha v$  integrin receptor antagonizing effect is an  $\alpha v\beta 5$  antagonizing effect.

**Claim 19 (Presently Withdrawn)** The method of Claim 18 wherein the  $\alpha v\beta 5$  antagonizing effect is selected from the group consisting of inhibition of restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth.

**Claim 20 (Presently Withdrawn)** The method of Claim 13 wherein the  $\alpha v$  integrin receptor antagonizing effect is a dual  $\alpha v\beta 3/\alpha v\beta 5$  antagonizing effect.

**Claim 21 (Presently Withdrawn)** The method of Claim 20 wherein the dual  $\alpha v\beta 3/\alpha v\beta 5$  antagonizing effect is selected from the group consisting of inhibition of bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth.

**Claim 22 (Presently Withdrawn)** A method of eliciting an  $\alpha v$  integrin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 9.

**Claim 23 (Presently Withdrawn)** A method of treating or preventing a condition mediated by antagonism of an  $\alpha v$  integrin receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 9.

**Claim 24 (Presently Withdrawn)** A method of treating metastatic tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound according to Claim 1 in combination with radiation therapy.